Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trilaciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 16/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CCND1 | P24385 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 9/20 | 1.00 |
| ▸ | CCND3 | P30281 | 3/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | TTK | P33981 | 1/20 | 0.83 |
| ▸ | FLT3 | P36888 | 1/20 | 0.83 |
| ▸ | CCNH | P51946 | 1/20 | 0.83 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.83 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.83 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trilaciclib SCHEMBL10082028 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29763763 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29514690 | 0.99 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29375833 | 0.99 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL4549924 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL10082029 | 0.93 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551643 | 0.93 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959535 | 0.92 | CDK2 (0.86) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959189 | 0.91 | CDK2 (0.84) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22005227 | 0.91 | CDK2 (0.84) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2150 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| CN-122075701-A | Use of NUAK A2 inhibitor in preparation of medicines for preventing or/and treating pulmonary fibrosis | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026101937-A1 | COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF | ATOSSA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4704841-A1 | IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER | Eli Lilly and Company (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| WO-2022090746-A1 | NMT INHIBITORS FOR TREATING SENESCENCE-ASSOCIATED DISEASES OR DISORDERS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-05 | — | — | WO | claimed |
| WO-2022082056-A1 | DOSING REGIMENS FOR CYCLIN‑DEPENDENT KINASE 7 (CDK7) INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022076779-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2022-04-14 | — | — | WO | claimed |
| US-20220096482-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-03-31 | — | — | US | claimed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | claimed |
| WO-2022040626-A1 | COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE AND A PROBIOTIC | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| WO-2022040628-A1 | COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE, A PROBIOTIC, AND SEMAPHORIN | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| US-20220054488-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-02-24 | — | — | US | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| EP-3715850-B1 | METHOD AND APPARATUS FOR DETERMINING SENSITIVITY OF CYCLIN-DEPENDENT KINASE 4/6 INHIBITOR | SYSMEX CORP (JP) | 2022-01-26 | — | — | EP | claimed |